Open AccessHigh-Dose versus Standard-Dose Tigecycline Treatment of Secondary Bloodstream Infections Caused by Extensively Drug-Resistant Acinetobacter baumannii: An Observational Cohort Study
Author(s) -
Hui Han,
Weidong Qin,
Yue Zheng,
Dongming Cao,
Haining Lü,
Lu Zhang,
Yi Cui,
Yuanyuan Hu,
Wei Li,
Haipeng Guo,
Dawei Wu,
Chen Li,
Hao Wang,
Yuguo Chen
Publication year - 2021
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s322803
Subject(s) - tigecycline , medicine , acinetobacter baumannii , minocycline , antibiotics , microbiology and biotechnology , genetics , bacteria , pseudomonas aeruginosa , biology
Extensively drug-resistant Acinetobacter baumannii (XDR-AB) infections have become difficult to treat and are associated with a high mortality rate. Tigecycline is one of the most effective agents used to treat XDR-AB infections, but data from treating bloodstream infection (BSI) in standard dose do not look promising, because of its low plasma concentration. Secondary BSI with primary infection source may indicate tigecycline treatment with a higher dose. Currently, little is known about the application of high-dose tigecycline among patients with secondary BSI caused by XDR-AB. We aimed to investigate the outcomes for high-dose (HD) tigecycline treatment versus standard-dose (SD) treatment of these patients.